James Martin - Cocrystal Pharma CFO

COCP Stock  USD 1.50  0.01  0.67%   

CFO

Mr. James J. Martin is Chief Financial Officer of the company. He has served as Chief Financial Officer of NonInvasive Monitoring Systems, Inc. since January 2011. Since November 2016, he has served as Chief Financial Officer of Motus GI Holdings, Inc, a privately held medical device company. From September 2014 to November 2016 Mr. Martin served as Chief Financial Officer of VBI Vaccines Inc., a pharmaceutical development and manufacturing company. From April 2014 to September 2015, Mr. Martin served as Chief Financial Officer of Vapor Corporationration Inc., a vaporizer retail and wholesale company. From January 2011 to October 2, 2013, Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc. since 2017.
Age 49
Tenure 7 years
Address 19805 North Creek Parkway, Bothell, WA, United States, 98011
Phone305 425 1780
Webhttps://www.cocrystalpharma.com

Cocrystal Pharma Management Efficiency

The company has return on total asset (ROA) of (0.3194) % which means that it has lost $0.3194 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4831) %, meaning that it created substantial loss on money invested by shareholders. Cocrystal Pharma's management efficiency ratios could be used to measure how well Cocrystal Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2024, Return On Capital Employed is likely to drop to -0.93. In addition to that, Return On Assets is likely to drop to -1.15. At this time, Cocrystal Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/28/2024, Non Current Liabilities Other is likely to grow to about 366.4 K, while Total Current Liabilities is likely to drop slightly above 1 M.
The company currently holds 297 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cocrystal Pharma has a current ratio of 17.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cocrystal Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Cocrystal Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cocrystal Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cocrystal to invest in growth at high rates of return. When we think about Cocrystal Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

CFO Age

Maddalena Liso23Andme Holding Co
N/A
Peter KanniahEquillium
N/A
Mardi DierMadrigal Pharmaceuticals
60
Eric ShaffSeres Therapeutics
42
Bjorn Rosendahl23Andme Holding Co
59
Didier HirschAgilent Technologies
66
Jonathan CPAMoleculin Biotech
60
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious andor chronic viral diseases. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp Dohme Corp. to discover and develop proprietary influenza AB antiviral agents a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections and drug discovery collaboration with HitGen and InterX Inc. Cocrystal Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. Cocrystal Pharma (COCP) is traded on NASDAQ Exchange in USA. It is located in 19805 North Creek Parkway, Bothell, WA, United States, 98011 and employs 12 people. Cocrystal Pharma is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Cocrystal Pharma Leadership Team

Elected by the shareholders, the Cocrystal Pharma's board of directors comprises two types of representatives: Cocrystal Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cocrystal. The board's role is to monitor Cocrystal Pharma's management team and ensure that shareholders' interests are well served. Cocrystal Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cocrystal Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Roger Kornberg, Chairman, CoFounder
CPA CPA, CFO CoCEO
Curtis Dale, Interim CFO
Steven Rubin, Director
Sam Lee, Co-Founder and Pres
Raymond Schinazi, Director
Gary Wilcox, Co-Founder, Vice Chairman, Sr. Advisor and Member of Scientific Review Committee
James Martin, CFO
Jeffrey Meckler, CEO and Director
Anthony Japour, Director
Phillip Frost, Director
David Block, Director
Douglas Mayers, Chief Marketing Officer
Walt Linscott, Director
Jane Hsiao, Director
Todd Brady, Director

Cocrystal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cocrystal Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cocrystal Stock

  0.64MBRX Moleculin Biotech Upward RallyPairCorr
  0.71MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Cocrystal Stock

  0.83DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.8MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.8MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.76EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.71MDWD Mediwound Financial Report 4th of June 2024 PairCorr
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cocrystal Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cocrystal Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cocrystal Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Cocrystal Pharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.
Note that the Cocrystal Pharma information on this page should be used as a complementary analysis to other Cocrystal Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Cocrystal Stock analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Bonds Directory
Find actively traded corporate debentures issued by US companies
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Cocrystal Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cocrystal Pharma. If investors know Cocrystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cocrystal Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.97)
Revenue Per Share
0.006
Quarterly Revenue Growth
0.269
Return On Assets
(0.32)
Return On Equity
(0.48)
The market value of Cocrystal Pharma is measured differently than its book value, which is the value of Cocrystal that is recorded on the company's balance sheet. Investors also form their own opinion of Cocrystal Pharma's value that differs from its market value or its book value, called intrinsic value, which is Cocrystal Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cocrystal Pharma's market value can be influenced by many factors that don't directly affect Cocrystal Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cocrystal Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cocrystal Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cocrystal Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.